Liquid Biopsies to Evaluate Immunogenicity of Gynecological/Breast Tumors: On the Way to Blood-Based Biomarkers for Immunotherapies | Zendy

Corinna Keup | Zendy; Rainer Kimmig | Zendy; Sabine KasimirBauer | Zendy

Open Access

Liquid Biopsies to Evaluate Immunogenicity of Gynecological/Breast Tumors: On the Way to Blood-Based Biomarkers for Immunotherapies

Author(s) -

Corinna Keup,

Rainer Kimmig,

Sabine KasimirBauer

Publication year - 2020

Publication title -

breast care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.767

H-Index - 30

eISSN - 1661-3805

pISSN - 1661-3791

DOI - 10.1159/000510509

Subject(s) - medicine , liquid biopsy , immunogenicity , immune system , biomarker , circulating tumor cell , microsatellite instability , breast cancer , immunotherapy , oncology , cancer research , biopsy , cancer , immunology , metastasis , biology , biochemistry , allele , gene , microsatellite

Despite the assumption of breast cancer (BC) as a cold, non-immunogenic tumor, immune checkpoint inhibitor (ICI) therapy is favorable for a subgroup of patients. Immunohistochemical assessment of the programmed cell death ligand 1 (PD-L1) is the only approved companion diagnostic for anti-PD-L1 therapy in metastatic triple-negative BC; however, challenges regarding the standardization of PD-L1 scoring in tumor tissue still remain. Consequently, to select patients most likely to respond to ICI, blood-based biomarkers are urgently needed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research